ACR/ARHP 2008 Daily News Exhibit Guide - (Page 2)

PARTIAL RESPONDER? NEW RESPONSE. Introducing Avise PG — The first and only test to measure methotrexate polyglutamates, the active metabolites of MTX SM As a prodrug, methotrexate (MTX) requires enzymatic conversion to MTX polyglutamates to exert anti-inflammatory and immunomodulatory effects in rheumatoid arthritis (RA). However, MTX absorption, metabolism, and excretion vary widely between individuals, leading to marked variability in the conversion of MTX to its active, polyglutamated forms. Because of this variability, dose and response do not always correlate, making it challenging to optimize MTX therapy without insight into the patient’s metabolism. But now there is Avise PG, a test that can help you determine whether partial or nonresponders to MTX may benefit from continued dose escalation or may need a change in therapy. Avise PG is the key to objectively evaluating MTX metabolism and giving your RA patients their best chance for a new response. Visit us in San Francisco, Booth 1533 www.avisetest.com References: 1. Kremer JM. Arthritis Rheum. 2004; 50(5):1370-1382. 2. Hoekstra M, et al. J Rheum. 2004; 31(4):645-648. 3. Chládek J, et al. Eur J Clin Pharmacol. 1998; 53(6):437-444. 4. Dervieux T, et al. Arthritis Rheum. 2004; 50(9):2766-2774. Avise PG and the Avise PG logo are service marks of Cypress Bioscience, Inc. The Cypress Bioscience, Inc., logo is a registered trademark of Cypress Bioscience, Inc. © 2008 Cypress Bioscience, Inc. San Diego, CA. All rights reserved. 30-0008.0 http://www.avisetest.com http://www.avisetest.com

Table of Contents Feed for the Digital Edition of ACR/ARHP 2008 Daily News Exhibit Guide

ACR/ARHP 2008 Daily News Exhibit Guide

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.